Skip to content
Home/Companies/Biotech/Caraway Therapeutics

Caraway Therapeutics

Biotech·United States·Exited 2023·Held 6yr
Entry
2017
Hold
6yr
Exit
2023

Who owns Caraway Therapeutics?

Caraway Therapeutics was owned by SV Health Managers through Dementia Discovery Fund (2015 vintage) from 2017 to 2023, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-16

SV Health Managers
Investor
SV Health Managers
Dementia Discovery Fund · 2015 · Impact

Key facts

HQUnited States
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2023

More from Dementia Discovery Fund

Other portfolio companies in the same fund.

Montara Therapeutics
Active
BiotechUnited States· 2024
TRIMTECH Therapeutics
TRIMTECH Therapeutics
Active
BiotechUK· 2023
Amphista Therapeutics
Amphista Therapeutics
Active
BiotechUK· 2022
AviadoBio
AviadoBio
Active
BiotechUK· 2021
Harness Therapeutics
Harness Therapeutics
Active
BiotechUK· 2020
NRG Therapeutics
Active
BiotechUK· 2020

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Caraway Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Caraway Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue